期刊文献+

耐甲氧西林金黄色葡萄球菌对抗菌药物MIC值的监测 被引量:20

Surveillance on MIC of Antibiotic Resistance of Meticillin-resistant Staphylococcus aureus
原文传递
导出
摘要 目的了解医院5年分离的耐甲氧西林金黄色葡萄球菌(MRSA)对抗菌药物MIC值的变迁。方法用Etest法检测临床分离的MRSA对万古霉素、替考拉宁和利奈唑烷的MIC值。结果2003-2007年5年内,MRSA检出率从2003年的52.2%上升到2007年的74.5%,万古霉素的MIC几何均数从1.85μg/ml上升到2.15μg/ml,替考拉宁的MIC几何均数从1.28μg/ml上升到2.07μg/ml,利奈唑烷的MIC值的变化不大。结论2003-2007年5年内,MRSA检出率逐年上升,MRSA对万古霉素、替考拉宁的MIC值有升高的趋势,且以替考拉宁的升高更为明显。 OBJECTIVE To review and analyze the change in the MICs of vancomycin, teicoplanin and linezolid in meticillin-resistant Staphylococcus aureus (MRSA) strains isolated in our hospital from 2003 to 2007. METHODS The MICs of vancomycin, teicoplanin and linezolid were tested by Etest method on a sample of randomly selected MRSA strains. RESULTS The incidences of MRSA increased from 52.2% in 2003 to 74.5% in 2007. MIC of vancomycin increased from 1. 85 μg/ml in 2003 to 2. 15 μg/ml in 2007, and teicoplanin MIC geometric mean increased even more markedly from 1.28 μg/ml in 2003 to 2.07 μg/ml in 2007. The linezolid MIC remained almost unchanged. CONCLUSIONS The incidences of MRSA were increasing from 2003 to 2007. There is a upward trend in MIC of glycopeptide over the years, in which the increase for teicoplanin is higher than others two.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2009年第11期1407-1409,共3页 Chinese Journal of Nosocomiology
关键词 耐甲氧西林金黄色葡萄球菌 万古霉素 替考拉宁 利奈唑烷 MRSA Vancomycin Teicoplanin Linezolid
  • 相关文献

参考文献9

  • 1Robert J, Bismuth R, Jarlier V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus:a 20 year study in a large French teaching hospital, 1983-2002 [J]. J of Antimicrob Chemother, 2006,57(3) : 506-510.
  • 2Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001[J]. Clin Infect Dis, 2003,36 (4):429-439.
  • 3Kotilainen P, Routamaa M, Peltonen R, et al. Elimination of epidemic methicillin-resistant Staphylococcus aureus from a university hospital and district institutions,Finland[J]. Emerg Infect Dis,2003,9(2) : 169-175.
  • 4Centers for Diseases Control. Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997[J]. Morb Mortal Wky Reo,1997,46(35):813-814.
  • 5王岱明.耐药菌院内感染及其防治[J].中华儿科杂志,2002,40(8):455-456. 被引量:9
  • 6Mcneil SA, Clark NM, Chandrasekar PH, et al. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with Synercid (quinupristin-dalfopristin) [J]. Clin Infect Dis, 2000,30 (2) : 403-404.
  • 7Stevens DL, Herr D, Larnpipis H, et al. Linezolid versus vancomycin for the treatment of methicilin-resistant Staphylococcus aureus infection[J]. Clin Infect Dis,2002,34(11) : 1481-1490.
  • 8Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU2100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia [J]. Clin Infect Dis, 2001,32(3) :402-412.
  • 9朱健铭,吴康乐,姜如金.221株耐甲氧西林金黄色葡萄球菌qacA/qacB基因检测及临床意义[J].中华医院感染学杂志,2008,18(11):1522-1524. 被引量:22

二级参考文献15

共引文献29

同被引文献147

引证文献20

二级引证文献130

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部